100 related articles for article (PubMed ID: 19698930)
1. Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.
Galili N; Raza A
Best Pract Res Clin Haematol; 2009 Jun; 22(2):223-37. PubMed ID: 19698930
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Wu L; Li X; Xu F; Chang C; He Q; Zhang Z; Zhang Y
Ann Hematol; 2012 Oct; 91(10):1547-54. PubMed ID: 22580751
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplasia: the good, the fair and the ugly.
Schiffer CA
Best Pract Res Clin Haematol; 2007 Mar; 20(1):49-55. PubMed ID: 17336254
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
Giachelia M; D'Alò F; Fabiani E; Saulnier N; Di Ruscio A; Guidi F; Hohaus S; Voso MT; Leone G
Leuk Res; 2011 Apr; 35(4):465-71. PubMed ID: 20869114
[TBL] [Abstract][Full Text] [Related]
5. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes.
Roela RA; Carraro DM; Brentani HP; Kaiano JH; Simão DF; Guarnieiro R; Lopes LF; Borojevic R; Brentani MM
Leuk Res; 2007 May; 31(5):579-89. PubMed ID: 17092558
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
7. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Oliva EN; Cuzzola M; Aloe Spiriti MA; Poloni A; Laganà C; Rigolino C; Morabito F; Galimberti S; Ghio R; Cortelezzi A; Palumbo GA; Sanpaolo G; Finelli C; Ricco A; Volpe A; Rodà F; Breccia M; Alimena G; Nobile F; Latagliata R
Ann Hematol; 2013 Jan; 92(1):25-32. PubMed ID: 22983750
[TBL] [Abstract][Full Text] [Related]
8. Translational research in myelodysplastic syndromes.
Raza A; Qawi H; Mehdi M; Mumtaz M; Galili N
Rev Clin Exp Hematol; 2004 Dec; 8(2):E2. PubMed ID: 16027100
[TBL] [Abstract][Full Text] [Related]
9. Are new agents really making a difference in MDS?
Stone RM
Best Pract Res Clin Haematol; 2008 Dec; 21(4):639-46. PubMed ID: 19041603
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
[TBL] [Abstract][Full Text] [Related]
11. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
12. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
13. Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin.
Mhyre AJ; Deeg HJ
Leuk Res; 2007 Jun; 31(6):747-9. PubMed ID: 17320170
[No Abstract] [Full Text] [Related]
14. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.
Chan AC; Neeson P; Leeansyah E; Tainton K; Quach H; Prince HM; Godfrey DI; Ritchie D; Berzins SP
Leukemia; 2010 Mar; 24(3):592-600. PubMed ID: 20072154
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.
Monika Belickova M; Merkerova MD; Votavova H; Valka J; Vesela J; Pejsova B; Hajkova H; Klema J; Cermak J; Jonasova A
Int J Hematol; 2016 Nov; 104(5):566-573. PubMed ID: 27416819
[TBL] [Abstract][Full Text] [Related]
16. New therapeutics for myelodysplastic syndromes.
List AF
Leuk Res; 2012 Dec; 36(12):1470-4. PubMed ID: 22959510
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of myelodysplastic syndromes.
Galili N; Raza A
Expert Opin Pharmacother; 2010 Aug; 11(11):1889-99. PubMed ID: 20486832
[TBL] [Abstract][Full Text] [Related]
18. Evaluating new treatment options for MDS.
Garcia-Manero G; Yang AS; Jagasia M
Clin Adv Hematol Oncol; 2007 Nov; 5(11):1-9; quiz 10-2. PubMed ID: 18185491
[TBL] [Abstract][Full Text] [Related]
19. New agents in the treatment of MDS.
List AF
Clin Adv Hematol Oncol; 2005 Nov; 3(11):832-4. PubMed ID: 16491623
[No Abstract] [Full Text] [Related]
20. Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome.
Gueller S; Komor M; Nowak D; Baldus CD; de Vos S; Hoelzer D; Ottmann OG; Hofmann WK
Exp Hematol; 2010 Sep; 38(9):718-32, 732.e1-6. PubMed ID: 20621626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
